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The aim of this study was to determine the minimal important difference for the six-minute
walk distance in people with diffuse parenchymal lung disease.
Methods: Forty-eight subjects (24 idiopathic pulmonary fibrosis) undertook the six-minute
walk test before and after an 8-week exercise program. The minimal important difference
was calculated using a distribution-based and an anchor-based method. A global rating of
change scale was used as the external criterion to judge patients as clinically unchanged or
changed.
Results: The mean change in six-minute walk distance in improved subjects was 50.0 m,
compared to 4.0 m in unchanged subjects and a reduction of 64.3 m in those classified as worse
(p< 0.001). The receiver operating characteristic curve indicated a cut-off value for meaning-
ful change of 30.5 m (area under the curve 0.89, 95% confidence interval 0.81e0.98) whilst the
standard error of the mean method indicated a value of 33 m. Similar values were obtained
when only subjects with idiopathic pulmonary fibrosis were included (29 and 34 m, respec-
tively).
Conclusions: Small differences in six-minute walk distance, in the range 29e34 m, may be clin-
ically significant for people with diffuse parenchymal lung disease.
ª 2009 Elsevier Ltd. All rights reserved.of Physiotherapy, Alfred Hospital, Commercial Road, Melbourne 3004, Australia. Tel.: þ61 3 9076
org.au (A.E. Holland).
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The diffuse parenchymal lung diseases (DPLDs) are a diverse
group of chronic lung conditions characterized by exercise
limitation and dyspnea on exertion.1,2 Treatment options are
limited and are frequently associated with significant risks
and side effects. In this setting, it is important to know
whether changes in functional status are associated with
sufficient clinical benefit to warrant a change in a patient’s
medical management. The magnitude of this change is
referred to as the minimal important difference (MID).3
The six-minute walk distance (6MWD) is a widely used
measure of functional status in people with DPLD. The
distance walked is closely linked to disease severity and
survival across a range of DPLDs4e6 and is an important
outcomemeasure for clinical trials.7,8 To date theMID for the
6MWD in DPLD has not been established. Previous investiga-
tors have identified a distance of 54 m for the MID in people
with COPD,9 although more recently this value has been
questioned and the threshold for clinically important change
may be lower.10 It is likely that differences in pathophysi-
ology between the two conditions preclude the direct
adoption of these findings in DPLD. The lack of a description
of the MID for this patient group is a major limitation to
interpretation of longitudinal change in functional status.
A variety of methodologies have been used to calculate
the MID. Although a previous approach has been to examine
cross-sectional differences in 6MWD9 there is evidence that
cross-sectional differences (differences between patients at
a given time point) do not correspond to longitudinal differ-
ences (within one individual over time).11 It has therefore
been suggested that the MID should be determined using
methods that focus on change within individuals.12
Available methods for determining the MID can be classi-
fied as either anchor-based or distribution-based.13 Anchor-
basedmethods involve comparing apatient’s change score to
another measure of clinically relevant change, such as
a global rating of change score completed by the patient
and/or clinician.14 Some authors suggest that the patient’s
perspective is the most relevant when assessing change in
functional status3; however, limitations to patient recall
have previously resulted in low correlations between
patient-reported anchors and 6MWD.9 Distribution-based
methods, such as the standard error of the measurement
(SEM), are built on the statistical properties of the study
results. One SEM has been shown to closely approximate the
MID.15 The SEM has the advantages of being independent of
the sample characteristics and takes into consideration the
possibility that some of the observed change is due to
measurement error.16 Concurrent comparisons using both
approaches are recommended to evaluate the effects of the
methodology on the final value.17 The aimof this studywas to
determine the MID for the 6MWD in people with DPLD using
both an anchor-based and a distribution-based method.
Material and methods
Study subjects
Patients with documented DPLD were recruited from two
tertiary hospitals. For IPF, the diagnostic criteria wereconsistent with those outlined in the International
Consensus Statement.18 Patients were eligible to partici-
pate if they were ambulant and reported dyspnea on
exertion on stable medical therapy. Exclusion criteria were
a history of syncope on exertion or any comorbidities which
precluded exercise training. All subjects gave written
informed consent and the study was approved by the
human ethics committees at both sites.
Study design
The six-minute walk test was measured on two occasions,
eight weeks apart, using a standardised protocol.19 All
subjects undertook two tests on each testing occasion and
the best distance was recorded. Use of supplemental
oxygen during the test was standardised between subjects
and testing occasions as previously described in subjects
with DPLD.4
Methods
Subjects participated in an eight-week exercise training
program conducted according to accepted guidelines for
patients with chronic respiratory disease.20 Some were
participants in a randomised controlled trial evaluating the
efficacy of exercise training inDPLD.21 Following the exercise-
trainingperiod, butbefore repeating the six-minutewalk test,
subjects were asked tomake a global rating of change in their
walking ability by an independent data collector (a physio-
therapist who was not known by the participants and had not
been involved in their training). Participants were asked ‘Has
therebeenanychange inyourwalkingability sinceyoustarted
the pulmonary rehabilitation program?’ and could answer
either ‘worse’, ‘about the same’ or ‘better’.22 If subjects
stated that they were worse, they were asked whether they
were ‘much worse’ or ‘a little worse’. If subjects stated that
they were better, they were asked whether they were ‘much
better’ or ‘a little better’. At the same time point, clinicians
who trained the participants in the pulmonary rehabilitation
class were asked to rate the change in the participant’s
walkingusing the samecriteria,whilst blinded to the subject’s
own rating. Both participants and clinicians were therefore
blinded to the second 6MWD at the time of undertaking the
global rating of change. If participants indicated there had
been no change in their walking ability they were classified as
‘unchanged’. If participants indicated any degree of
improvement or worsening on this scale, they were classified
as ‘changed’.22Comparisonofparticipantandclinician ratings
was used to verify patient recall.14
Analyses
The MID for the 6MWD was calculated using both anchor-
based and distribution-based methods. For the anchor-
based method, the sensitivity and specificity for change in
6MWD to discriminate between individuals who had been
classified as ‘changed’ or ‘unchanged’ were calculated. A
receiver operating characteristic (ROC) curve was obtained
by plotting the sensitivity (Y-axis) against 1-specificity
(X-axis) for each of the cut-off values.14 The MID for the
6MWD was determined by visual inspection of the ROC
1432 A.E. Holland et al.curve. The 95% confidence interval for the MID was found
using the bootstrap.23 In each case, 1000 bootstrap repli-
cate samples were obtained, by resampling the ‘‘changed’’
and ‘‘unchanged’’ samples separately. For each replicate
sample the optimal cut-point was obtained. The limits of
the 95% confidence interval were then taken to be the 2.5th
and 97.5th percentile of the 1000 cut-points. Minitab
version 15.1 and some associated programming were used
to carry out the bootstrapping. For the distribution-based
method, the SEM was calculated using the revised Jacobsen
formula.24 Calculations were repeated for the subgroup of
participants with IPF. The reliability coefficient for the
6MWD was obtained from a previous study of the 6MWD in
subjects with IPF.25
Univariate analysis of variance was used to assess the
effects of gender, age (65 years vs >65 years), baseline
walking distance (<350 vs 350 m) 26 and disease severity
(TLCO 39% predicted vs >39% predicted)27 on change in
walk distance. Statistical analysis was undertaken with SPSS
version 14.0. Further detail regarding statistical methods is
provided in Supplementary data.
Results
Forty-eight subjects with DPLD were recruited. Demo-
graphic characteristics of the included subjects are shown
in Table 1. There was a wide range of walking ability with
6MWD ranging from 154 to 681 m. Participants reported
a moderate degree of dyspnea (median MRC dyspnea
scoreZ 3, range 1e5). Twenty-four subjects had a diag-
nosis of IPF, while 20 subjects had diffuse parenchymal lung
disease of known cause (collagen vascular disease, drug or
dust-related) and four subjects had granulomatous lung
disease. There were no differences between participants
with and without IPF in either baseline 6MWD (pZ 0.24) or
the change in 6MWD following the exercise program
(pZ 0.61). Respiratory function did not change over the
eight-week study period.
Forty-three of the 48 subjects completed the exercise
program; 4 of the 5 participants who did not complete had
IPF. Followup data were obtained from all participants
regardless of completion. The range of differences in 6MWD
between the beginning and the end of the program ranged
from an improvement of 128 m to a decrease of 115 m. The
patient-completed global rating of change score indicated
improvement in 26 subjects, whilst 15 subjects wereTable 1 Demographic characteristics of subjects at
baseline (nZ 48).
Mean (standard deviation) Range
Age, years 69 (9) 48e84
FVC %pred 78 (16) 32e119
TLCO %pred 51 (18) 19e91
TLC %pred 76 (16) 47e101
RVSP (mmHg) 37 (13) 16e71
6MWD m 403 (118) 154e681
Data aremean (standard deviation). FVCe forced vital capacity;
%pred e percentage predicted; TLCO e diffusing capacity for
carbon monoxide; TLC e total lung capacity; RVSP e right
ventricular systolic pressure; 6MWD e six-minute walk distance.classified as unchanged and 7 subjects were classified as
worse. The mean change in 6MWD in those subjects who
were classified as improved was 50.0 m, compared to
a mean change of 4.0 m in those classified as unchanged
and a mean reduction of 64.3 m in those who were classi-
fied as worse (p< 0.001, Fig. 1). There were no differences
in the degree of change in 6MWD that was classified as
clinically important related to gender (pZ 0.98), severity
of lung disease (pZ 0.55) or age (pZ 0.86, Fig. 2). There
was a trend towards larger changes in walking distance
being required to specify that clinically important change
had occurred in those with a baseline 6MWD of less than
350 m (pZ 0.1).
The ROC curve for all participants is depicted in Fig. 3a.
The area under the curve was 0.89 (95% confidence interval
0.81e0.98). Visual inspection indicates that the cut-off
value at the upper left corner representing the best
balance between sensitivity and specificity for this test to
reflect meaningful change in the 6MWD is 30.5 m (95%
confidence interval 19e45 m). This point corresponds to
a sensitivity of 0.73 and a specificity of 0.94. When the
analysis was repeated including only subjects with IPF, the
area under the curve was 0.93 (95% confidence interval
0.83e1.03) with a cut-off value of 29 m (95% confidence
interval 19e45 m, Fig. 3b).
Using the baseline standard deviation for the 6MWD and
the reliability coefficient for the 6MWD (rZ 0.96), the SEM
for 6MWD in all participants was calculated to be 33 m.
When only participants with IPF were included, the SEM was
34 m. There was excellent agreement between the number
of participants who were classified as changed under the
ROC and SEM methods (kappaZ 0.96 for all participants,
95% confidence interval 0.88e1.0; kappaZ 0.92 for IPF
participants, 95% confidence interval 0.80e1.0).
There was good agreement between patients and clini-
cians regarding clinical change, with consensus occurring in
38 subjects (79%). There were no differences in diagnoses,
respiratory function, baseline 6MWD or change in 6MWD
following the exercise program between those subjects in
whom consensus was or was not observed. The ROC curveFigure 1 Relationship between change in six-minute walk
distance and global rating of change in walking ability following
exercise training. Data aremeans and standard deviations. 6MWD
e six-minute walk distance. Univariate analysis of variance indi-
cates a significant difference between groups (p< 0.001).
Figure 2 Change in six-minute walk distance according to
gender, disease severity, age and baseline walk distance. No
effect of baseline demographic variables was found in partic-
ipants who were rated as either changed or unchanged on the
global rating of change score. Data are means and standard
deviations. TLCO e diffusing capacity for carbon monoxide;
6MWD e six-minute walk distance.
Figure 3 Receiver operating characteristic curves for change
in six-minute walk distance; (a) all participants; (b) IPF
participants only.
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occurred revealed a cut-off for meaningful change of
30.5 m whilst the SEM method was 32 m. When the analyses
were repeated excluding those participants who reported
deterioration, the ROC and SEM estimates of the MID were
slightly lower (28.5 and 24 m, respectively).
Discussion
This study demonstrates that small changes in 6MWD are
perceived by both patients and clinicians to be clinically
significant for patients with DPLD. Using a longitudinal model
that focuses on important change within individuals, we have
determined that the difference in 6MWD which is associated
with noticeable change in functional status is between 29 and
34 m. The threshold for clinically significant change was not
different when only subjects with IPF were included.
This study used both anchor-based and distribution-based
methods to calculate the MID and found a difference of only
3 m between approaches. Both methods have desirable
features. The anchor-based method we selected14 takes into
account both patient and clinician perspectives, thus
strengthening the criterion for change. The ROC curve
providesameasureofboth sensitivity and specificity, allowing
clinicians to determine whether the cut-off point is appro-
priate for any given therapeutic intervention. This may be
important where the risks associated with false positives are
high (e.g. where treatment has toxic side effects). The high
specificity of our estimates indicates that false negatives are
very unlikely using the threshold of 30.5 m (Fig. 3). Based on
these data, clinicians can be confident that if the change in
6MWD does not achieve the threshold then it is very unlikely
that any significant change has occurred. The distribution-
based method has the advantage of consistency acrosssamples and thus can be applied across all but the extremes of
a given population’s ability levels.16 The similar result from
these two approaches is encouraging and suggests that the
estimate is robust.
The MID for the 6MWD determined here for patients with
DPLD is similar to the threshold for important change
recently reported in patients with COPD10 but lower than the
estimated MID for patients with pulmonary arterial hyper-
tension.28 Using data sets from previous trials which were
analysed using distribution-based methods, a threshold
value of 35 m was identified as representing an important
effect in patients with COPD.28 However, an anchor-based
estimate was not obtained from that study due to poor
correlations between patient-reported outcomes and
walking distance. In contrast, we found a strong relationship
between patient assessments and change in walking
distance. These differencesmay indicate thatwalking ability
is amore importantmeasure of change to patients with DPLD
than it is to those with COPD, perhaps due to differences in
pathophysiology and rapid disease progression in the former
group.5,29e31 However, it is more likely to be related to the
patient outcomes selected. Whereas previous authors used
quality of life measures which assess the broader impact of
lung disease on well-being, our prospective study used
a global rating of change scale specifically designed to assess
walking ability. AnMID of 41 mhas been reported for patients
1434 A.E. Holland et al.with pulmonary arterial hypertension,28 representing the
average of seven different distribution-based approaches
that ranged from 18.7 to 74.15 m. A patient anchor was not
available for use in this study. Anchor-based approaches are
the preferred method of assessing the MID where possible32
and provide confidence that the identified changes are
meaningful to patients.
Differences in the MID according to gender, age or disease
severity were not identified (Fig. 2). This is in accordance
with previous authors who have not identified any difference
in the MID for 6MWD according to baseline demographic
features.9 However, there was a trend towards a larger
difference in 6MWD being required to achieve clinical
significance in those with lower baseline walk distances.
These results should be interpreted with caution due to the
small numbers included in the subgroup analysis (nZ 13).
Larger trials are required to assess this in more detail.
This study has a number of limitations. Firstly, it was
conducted in the context of a randomised controlled trial of
exercise training for DPLD.21 Whether the results would be
similar in the context of other therapeutic interventions is
unclear. However, our sample included participants with
a wide range of disease severity and exercise tolerance
(Table 1) and thus it is likely that our results are broadly
applicable. Our sample did not include sufficient numbers
of subjects who deteriorated to assess whether the MID for
decline differed from the MID for improvement. Removal of
participants who had a ‘negative’ change in walking
distance resulted in slightly lower estimates of the MID that
were within the 95% confidence interval for the MID
calculated from the whole data set. Although some authors
suggest that positive and negative changes are pooled,22,33
others have indicated that there could be a difference in
the perception and meaning of positive and negative
changes.34 Larger samples followed across longer time
periods will be required to assess this important component
of the MID. Finally, we have focussed on the change in
walking distance as the primary indicator of clinically
significant change. Although many authors have reported
that 6MWD is a critical indicator of prognosis4,35,36 others
have suggested that desaturation during the six-minute
walk test may also be an important marker.2,29 The ampli-
tude of desaturation during exercise is poorly reproducible
in this population25 and we therefore chose not to evaluate
this in a study which required repeated measures.
In conclusion, this study demonstrates that the threshold
for clinically significant change in 6MWD for people with
DPLD is in the range of 30e33 m, and for people with IPF is
in the range 29e34 m. These values should be tested
further in the context of commonly used therapies for DPLD
and over a longer duration of follow-up.
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